Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Discovery and RIKEN GENESIS Sign Distribution Agreement

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
The agreement will see RIKEN GENESIS become sole distributor of Horizon’s molecular reference standards in Japan.

RIKEN GENESIS offers cutting-edge genomic products and services to a wide range of research institutions and corporations, and is a CAP (College of American Pathologists) accredited laboratory for genome analysis services. 

Reliable and renewable sources of reference standards are essential for molecular laboratories; however a lack of availability has previously been a major obstacle.  Even when patient samples are available, variability in DNA extraction and a lack of standardization have proven to be additional serious sources of error. Horizon’s HDx division has developed reliable and renewable genetically defined and thoroughly validated reference materials, providing an industry standard for the development of and quality control of molecular assays, thereby directly improving their accuracy.

Horizon’s Molecular Reference Standards include FFPE cell line blocks and purified gDNA. In early 2013 HDx launched its first Quantitative Multiplex DNA Reference Standard, intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS).

“Part of our mission at RIKEN GENESIS is to contribute to translating the results of genetic research into clinical settings,” said Yusuke Tsukahara, President and CEO, RIKEN GENESIS. “Horizon’s Molecular Reference Standards are a valuable step in the move towards practical implementation of personalized medicine, and we are delighted to be working with such a forward looking company.” 

“At the cutting edge of genome analysis, RIKEN GENESIS is an ideal partner for Horizon. We aim to affiliate ourselves with the best, like-minded companies for distribution; those dedicated to customer service, cutting edge science and ultimately better patient care,” commented Dr Brian Burke, Business Development Manager, Horizon Diagnostics. “We look forward to working with the team to develop the molecular reference standards market in Japan.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Partners with EMQN
Horizon to provide genetically defined human genomic reference standards for cancer diagnostics proficiency testing schemes.
Tuesday, March 27, 2012
Horizon and UK NEQAS ICC Announce Partnership to Improve Accuracy of Lung Cancer Diagnostic Testing
Horizon’s genetically defined human genomic reference standards to be used in FISH and IHC proficiency testing to help guide personalised medicine.
Tuesday, January 31, 2012
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!